Myeloperoxidase: a potential therapeutic target for coronary artery disease

Thanat Chaikijurajai,W. H. Wilson Tang

DOI: https://doi.org/10.1080/14728222.2020.1762177

IF: 6.797

2020-05-07

Expert Opinion on Therapeutic Targets

Abstract:<span><b>Introduction</b>: Coronary artery disease (CAD) poses significant morbidity and mortality globally. Despite significant advances in treatment interventions, residual cardiovascular risks remain unchecked. Recent clinical trials have shed light on the potential therapeutic benefits of targeting anti-inflammatory pathways. Myeloperoxidase (MPO) plays an important role in atherosclerotic plaque formation and destabilization of the fibrous cap; both increase the risk of atherosclerotic cardiovascular disease and especially CAD.<b>Areas covered</b>: This article examines the role of MPO in the pathogenesis of atherosclerotic CAD and the mechanistic data from several key therapeutic drug targets. There have been numerous interesting studies on prototype compounds that directly or indirectly attenuate the enzymatic activities of MPO, and subsequently exhibit atheroprotective effects; these include aminobenzoic acid hydrazide, ferulic acid derivative (INV-315), thiouracil derivatives (PF-1355 and PF-06282999), 2-thioxanthines derivative (AZM198), triazolopyrimidines, acetaminophen, N-acetyl lysyltyrosylcysteine (KYC), flavonoids, and alternative substrates such as thiocyanate and nitroxide radical.<b>Expert opinion</b>: Future investigations must determine if the cardiovascular benefits of direct systemic inhibition of MPO outweigh the risk of immune dysfunction, which may be less likely to arise with alternative substrates or MPO inhibitors that selectively attenuate atherogenic effects of MPO.</span>

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of myeloperoxidase (MPO) in coronary artery disease (CAD) and evaluate its potential as a potential treatment target. Specifically, the paper focuses on the following aspects:

1. **The role of MPO in atherosclerosis**: The paper elaborates in detail how MPO participates in the occurrence and development of atherosclerosis by oxidizing low - density lipoprotein (LDL), changing the function of high - density lipoprotein (HDL), promoting endothelial dysfunction and weakening the stability of atherosclerotic plaques.

2. **The potential of MPO as a treatment target**: The paper discusses a variety of MPO inhibitors, including aminobenzoic acid hydrazide, ferulic acid derivatives (such as INV - 315), thiourea derivatives (such as PF - 1355 and PF - 0628999), 2 - thioxanthine derivatives (such as AZM198), etc. These compounds can directly or indirectly reduce the enzymatic activity of MPO, thus showing anti - atherosclerotic effects.

3. **Directions for future research**: The paper points out that future research needs to further determine whether the cardiovascular benefits of direct systemic inhibition of MPO outweigh the risks of immune dysfunction. In addition, it is also necessary to explore other alternative substrates or inhibitors that selectively inhibit the atherosclerotic effects of MPO.

In summary, this paper aims to provide theoretical basis and experimental basis for the development of new CAD treatment methods by in - depth analysis of the mechanism of MPO in CAD and its potential as a treatment target.